PMID- 33121429 OWN - NLM STAT- MEDLINE DCOM- 20201112 LR - 20201218 IS - 1528-3658 (Electronic) IS - 1076-1551 (Print) IS - 1076-1551 (Linking) VI - 26 IP - 1 DP - 2020 Oct 29 TI - IP-10 and MCP-1 as biomarkers associated with disease severity of COVID-19. PG - 97 LID - 10.1186/s10020-020-00230-x [doi] LID - 97 AB - BACKGROUND: COVID-19 is a viral respiratory disease caused by the severe acute respiratory syndrome-Coronavirus type 2 (SARS-CoV-2). Patients with this disease may be more prone to venous or arterial thrombosis because of the activation of many factors involved in it, including inflammation, platelet activation and endothelial dysfunction. Interferon gamma inducible protein-10 (IP-10), monocyte chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein 1-alpha (MIP1alpha) are cytokines related to thrombosis. Therefore, this study focused on these three indicators in COVID-19, with the hope to find biomarkers that are associated with patients' outcome. METHODS: This is a retrospective single-center study involving 74 severe and critically ill COVID-19 patients recruited from the ICU department of the Tongji Hospital in Wuhan, China. The patients were divided into two groups: severe patients and critically ill patients. The serum IP-10, MCP-1 and MIP1alpha level in both groups was detected using the enzyme-linked immunosorbent assay (ELISA) kit. The clinical symptoms, laboratory test results, and the outcome of COVID-19 patients were retrospectively analyzed. RESULTS: The serum IP-10 and MCP-1 level in critically ill patients was significantly higher than that in severe patients (P < 0.001). However, no statistical difference in MIP1alpha between the two groups was found. The analysis of dynamic changes showed that these indicators remarkably increased in patients with poor prognosis. Since the selected patients were severe or critically ill, no significant difference was observed between survival and death. CONCLUSIONS: IP-10 and MCP-1 are biomarkers associated with the severity of COVID-19 disease and can be related to the risk of death in COVID-19 patients. FAU - Chen, Yu AU - Chen Y AD - Department of Clinical Laboratory, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, 1 Shuaifuyuan Road, Beijing, 100730, China. FAU - Wang, Jinglan AU - Wang J AD - Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730, China. FAU - Liu, Chenxi AU - Liu C AD - Department of Clinical Laboratory, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, 1 Shuaifuyuan Road, Beijing, 100730, China. FAU - Su, Longxiang AU - Su L AD - Department of Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730, China. FAU - Zhang, Dong AU - Zhang D AD - Department of Clinical Laboratory, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, 1 Shuaifuyuan Road, Beijing, 100730, China. FAU - Fan, Junping AU - Fan J AD - Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730, China. FAU - Yang, Yanli AU - Yang Y AD - Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730, China. FAU - Xiao, Meng AU - Xiao M AD - Department of Clinical Laboratory, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, 1 Shuaifuyuan Road, Beijing, 100730, China. FAU - Xie, Jing AU - Xie J AD - Department of Infectious Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730, China. FAU - Xu, Yingchun AU - Xu Y AD - Department of Clinical Laboratory, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, 1 Shuaifuyuan Road, Beijing, 100730, China. FAU - Li, Yongzhe AU - Li Y AUID- ORCID: 0000-0002-0046-5276 AD - Department of Clinical Laboratory, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, 1 Shuaifuyuan Road, Beijing, 100730, China. yongzhelipumch@126.com. FAU - Zhang, Shuyang AU - Zhang S AD - Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, 1 Shuaifuyuan Road, Beijing, 100730, China. shuyangzhang103@163.com. LA - eng GR - 81671618/the National Natural Science Foundation of China/International GR - 81871302/the National Natural Science Foundation of China/International GR - CIFMS 2017-I2M-3-001/CAMS Innovation Fund for Medical Sciences/International GR - CIFMS 017-I2M-B&R-01/CAMS Innovation Fund for Medical Sciences/International PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20201029 PL - England TA - Mol Med JT - Molecular medicine (Cambridge, Mass.) JID - 9501023 RN - 0 (Adaptor Proteins, Signal Transducing) RN - 0 (Biomarkers) RN - 0 (CCL2 protein, human) RN - 0 (CXCL10 protein, human) RN - 0 (Chemokine CCL2) RN - 0 (Chemokine CXCL10) RN - 0 (MAPKAP1 protein, human) SB - IM MH - Adaptor Proteins, Signal Transducing/blood MH - Aged MH - Betacoronavirus/pathogenicity MH - Biomarkers/blood MH - COVID-19 MH - Chemokine CCL2/*blood MH - Chemokine CXCL10/*blood MH - Coronavirus Infections/*complications/diagnosis/mortality/virology MH - Critical Illness MH - Cytokine Release Syndrome/*complications/diagnosis/mortality/virology MH - Disseminated Intravascular Coagulation/*complications/diagnosis/mortality/virology MH - Female MH - Humans MH - Male MH - Middle Aged MH - Pandemics MH - Pneumonia, Viral/*complications/diagnosis/mortality/virology MH - Prognosis MH - Pulmonary Embolism/*complications/diagnosis/mortality/virology MH - Respiratory Insufficiency/*complications/diagnosis/mortality/virology MH - Retrospective Studies MH - SARS-CoV-2 MH - Severity of Illness Index MH - Survival Analysis PMC - PMC7594996 OTO - NOTNLM OT - COVID-19 OT - Critically ill patients OT - IP-10 OT - MCP-1 COIS- The authors declare no conflicts of interest. EDAT- 2020/10/31 06:00 MHDA- 2020/11/13 06:00 PMCR- 2020/10/29 CRDT- 2020/10/30 05:32 PHST- 2020/08/11 00:00 [received] PHST- 2020/10/20 00:00 [accepted] PHST- 2020/10/30 05:32 [entrez] PHST- 2020/10/31 06:00 [pubmed] PHST- 2020/11/13 06:00 [medline] PHST- 2020/10/29 00:00 [pmc-release] AID - 10.1186/s10020-020-00230-x [pii] AID - 230 [pii] AID - 10.1186/s10020-020-00230-x [doi] PST - epublish SO - Mol Med. 2020 Oct 29;26(1):97. doi: 10.1186/s10020-020-00230-x.